* Tonix Pharmaceuticals Holding Corp reported a quarterly adjusted loss of 86 cents per share for the quarter ended in December, higher than the same quarter last year, when the company reported EPS of $-3.50. The mean expectation of four analysts for the quarter was for a loss of $1.64 per share. Wall Street expected results to range from $-1.83 to $-1.46 per share.
* Revenue was $3.78 million; analysts expected $3.83 million.
* Tonix Pharmaceuticals Holding Corp's reported EPS for the quarter was a loss of 86 cents.
* The company reported a quarterly loss of $27.32 million.
* Tonix Pharmaceuticals Holding Corp shares had held steady so far this quarter and lost 53.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 23.3% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Tonix Pharmaceuticals Holding Corp is $5.50 This summary was machine generated from LSEG data April 1 at 10:09 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -1.64 -0.86 Beat
Sep. 30 2023 -1.49 -1.83 Missed
Jun. 30 2023 -2.75 -2.68 Beat
Mar. 31 2023 -3.03 -3.25 Missed
Comments